Is Axsome Therapeutics, Inc. (AXSM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.6% / 30% | 3.9% / 30% | 2.7% / 30% | 1.24% / 5% | ✓ HALAL |
| DJIM | 2.6% / 33% | 3.9% / 33% | 2.7% / 33% | 1.24% / 5% | ✓ HALAL |
| MSCI | 31.6% / 33% | 46.8% / 33% | 32.5% / 33% | 1.24% / 5% | ✗ NOT HALAL |
| S&P | 2.6% / 33% | 3.9% / 33% | 2.7% / 33% | 1.24% / 5% | ✓ HALAL |
| FTSE | 31.6% / 33% | 46.8% / 33% | 32.5% / 50% | 1.24% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 92.6% | |
| Operating Margin | -18.4% | |
| Net Margin | -28.7% | |
| Return on Equity (ROE) | -252.1% | |
| Return on Assets (ROA) | -16.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$93M |
| Free Cash Flow | -$94M |
| Total Debt | $218M |
| Debt-to-Equity | 247.0 |
| Current Ratio | 1.6 |
| Total Assets | $690M |
Price & Trading
| Last Close | $164.26 |
| 50-Day MA | $172.98 |
| 200-Day MA | $138.48 |
| Avg Volume | 684K |
| Beta | 0.5 |
|
52-Week Range
$86.99
| |
About Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.
Purification Calculator
As a halal stock with 1.24% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Axsome Therapeutics, Inc. (AXSM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Axsome Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Axsome Therapeutics, Inc.'s debt ratio?
Axsome Therapeutics, Inc.'s debt ratio is 2.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 31.6%.
Does Axsome Therapeutics, Inc. require dividend purification?
Yes, Axsome Therapeutics, Inc. has an impermissible income ratio of 1.24%, which means 1.24% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Axsome Therapeutics, Inc.'s key financial metrics?
Axsome Therapeutics, Inc. has a market capitalization of $8.0B, and revenue of $638M. The company maintains a gross margin of 92.6% and a net margin of -28.7%. Return on equity stands at -252.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.